A Different Approach for Cellular Oncogene Identification Came from Drosophila Genetics by Laura Monica Magdalena & Lorand Savu
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 12 
 
 
 
 
© 2013 Magdalena and Savu, licensee InTech. This is an open access chapter distributed under the terms of 
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
A Different Approach for Cellular Oncogene 
Identification Came from Drosophila Genetics 
Laura Monica Magdalena and Lorand Savu 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/54150 
1. Introduction 
1.1. Cancer is a genetic disease  
Cancer is a major health concern of our time, being responsible for more than 25% of deaths 
worldwide. The past two decades have produced strong evidence for the genetic basis of 
cancer. Cancer develops as a clonal disease occuring by the accumulation in multiple steps 
of genetic (or epigenetic) changes in oncogenes, tumor suppressor genes and “guardian” 
genes that support expansion of a new clone over the old one. Subsequently, it is the natural 
selection which helps expansion of a new clone carrying characteristics advantageous for 
proliferation [1, 2, 3].  
Nevertheless, the events contributing to cancer are not restricted to the cancer cells. The 
most encountered example is the case of NFkB (nuclear factor kappa-light-chain-enhancer of 
activated B cells) which is a protein complex that controls the transcription of DNA, that 
may be up-regulated in hepatocytes through different changes in the expression of TNF 
(Tumor Necrosis Factor) from the neighboring stromal inflammatory cells, and thus can 
become a key contributor in many cancer cells [3].  
Recently, it has been estimated that up to seven rate-limiting genetic / epigenetic events are 
needed for the development of a common human cancer [4]. These can appear in multiple 
different combinations depending on which particular tissue or cell-specific “anticancer” 
barriers are to be circumvented.  
A lot of knowledge about cancer was obtained from studying rare familial “monogenic” 
cancer syndromes. Although the most of the cancer cases appear to be “sporadic”, when 
cancer- causing gene mutations occurred only in adult somatic cells, these cases also proved 
to be important for understanding this intricate disease. Other important aspect refferes to 
the fact that many key molecular factors to cancer progression may not be deregulated at the 
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gene level. Downstream signaling proteins may become up-regulated by alterations in 
upstream growth factor signaling, altered catabolism, genes inactivated by epigenetic 
factors, protein expression altered by enzyme activity, degradation, chaperones, etc [4]. 
The idea that genes determine the growth behavior of a cell is now widely accepted, with 
abnormal growth reflecting the action of abnormal genes. The transformation of a normal 
cell to a cancer cell starts with changes in growth regulatory genes, and in the course of 
tumor progression further escape from normal growth control is caused by additional 
alterations in genes that direct cell multiplication and cell survival. Therefore, either somatic 
or germline mutations are both considered the root cause of cancer. These heritable changes 
in cancer cells are subsequently the targets for current attempts to develop effective and 
specific therapies for this disease [2]. As a general rule, one can say that most things related 
to cancer are a matter of timing and are determined by many other factors like the cell of 
origin, the mutations accumulated and the environment, together referred to as the 
molecular “road map” leading to cancer.  
At this time, more than 1% of all human genes are believed to be “cancer genes”. 
Approximately 90% of them represent somatic mutations in cancer, 20% bear germ-line 
mutations that predispose to cancer and 10% show both somatic and germ-line mutations 
[1]. Therefore, it was assumed that there are far fewer “pathways” implicated in cancer than 
genes. The identification of disease-related genes has led to a number of available genetic 
tests that detect disease or an individual’s risk of disease. Gene tests are available for 
different disorders and also in cancer testing, some good examples being for the BRCA1 
genes related to the breast cancer, or for MEN1 and RET genes which are linked with 
endocrine tumors. Once more disease linked-genes are discovered, more gene tests are 
expected to become available [1].  
1.1.1. The origin of cancer  
Cancer had been recognized throughout recorded history and was known to the ancient 
Egyptians, from around 1600 BC, but it was not studied until the seventeenth century, when 
the formal study of cancer (oncology) was first documented [1]. Nevertheless, only rather 
recently were registered spectacular progresses in describing the fundamental molecular 
basis of cancer, following the entry of molecular biology and especially of genetics.  
Usually, cancer is behaving exactly as a clonal disease, beginning with a mutational episode 
in a single cell and then develops in multiple stages through the acquisition of further 
mutations which are inherited through division, by the progeny of that cell. As the same 
outcome can also arise by epigenetic factors that alter chromatin structure, without altering 
the coding DNA, mutations are not the only way in which a cancer cell acquires inactivation 
or activation of a key gene/ protein. Therefore, sometimes the term “epimutations” is used 
to encompass both major routes by which cancer cells acquire aberrant expression/activity of 
key genes and proteins.  
The adult human has been estimated to contain in average as many as 1014 cells, most of 
which could theoretically become a cancer cell given the right sort of genetic (mutations) 
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and epigenetic changes. Replicating cells may be most vulnerable to cancer-causing 
mutations.  Even if some cell type, of which adult nerve cell are good examples, may avoid 
becoming cancer cell because they are essentially non-proliferating in the adult, most cells 
either regularly do or can at a pinch replicate [1]. It seems that most adult cells survive on 
average for 4-6 weeks and then have to be replaced. Also, over a thousand billion cells may 
die each day and are renewed either by replication of existing cells or from stem cells 
precursors. Given that every cell gets a significant amount of daily DNA damage and 1011 or 
more of them will replicate each day- that is a lot of potential cancer cells. Keeping this in 
mind a cancer might be expected to be a frequent incidence although so far this only 
happens in 1 in 3 people and usually even then only after 60 or 70 years of potentially 
mutation-causing events [1].  
It was well documented that there is a geographical variation in cancer incidence and death, 
and this likely reflects socioeconomic factors. The different roles of genetic predisposition, 
gene-environment interaction and infectious agents shared importance in causing cancer. 
Recent research points to the considerable overlap between the behavior of cancer cells and 
that of cells during normal physiological wound healing and during embryogenesis. 
Similarities refers to replication, less differentiated state, invasion/migration, with the major 
differences reflecting the lack of control and the unscheduled nature of replication which 
characterizes cancer. One intrigued question addressed later was how the organism is able 
to distinguish between normal growth and tissue repair (normal cell cycle) on one hand and 
neoplastic growth (cancer cell cycles) on the other. Several theories [2, 3] sustain that for the 
initial expansion of a clone of cells more than one mutation is needed. Efforts in several 
science laboratories sustain that in certain cases the mutational route to cancer may be rather 
short (in molecular terms) with as few as two interlocking mutations required for initiation 
or progression of cancer- especially in animal models, unlike in man where at least one of 
these lesions involves particularly “dangerous” oncogenes such as c-myc. Therefore, it is 
believed that at least in some cases the genetic basis of a given cancer may be remarkably 
simple. Reference genome for man and other model organisms from the last decade has 
helped the explosion of new knowledge in human genetics.  
1.2. The origin of oncogenes 
An oncogene is a gene that contributes to converting a normal cell into a cancer cell when 
mutated or expressed at abnormally-high levels. Although the discovery of the origin of 
oncogenes came in parallel with the study of retroviruses, known in general as cancer 
inductors, not all retroviruses are tumor viruses [4, 5]. Even from early 1972 many 
researchers set out to explore the "oncogene hypothesis" proposed by Robert J. Huebner and 
George J. Todaro of the National Cancer Institute [6]. Looking for one mechanism to explain 
the induction of cancer by many different agents, Huebner and Todaro had suggested that 
there are the retroviral oncogenes as part of the genetic baggage of all cells, perhaps 
acquired through viral infection early in evolution. They supposed that the oncogenes 
would be innocuous as long as they remained quiescent. When stimulated into activity by a 
carcinogenic agent, however, they could convert cells to cancerous growth. It was reasoned 
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that if the hypothesis was correct, the src (sarcoma) gene might be found in the DNA of 
normal cells. The copy of src could therefore be identified in the DNA from uninfected 
chickens and other birds. The next purpose was to find DNA related to src in mammals, 
including human beings, and in fishes. All vertebrates revealed to possess a gene related to 
src, and the oncogene hypothesis was consequently declared to be correct. But, on closer 
inspection, however, the gene that was discovered in vertebrates proved not to be a 
retrovirus gene at all. It was a cellular gene, which is now called c-src. The most convincing 
evidence for this conclusion came from the finding that the protein-encoding information of 
c-src is divided into several separate domains, called exons, by intervening regions known 
as introns. A split configuration of this kind is typical of animal-cell genes but not of the 
genes of retroviruses. Apart from their introns, the versions of c-src found in fishes, birds 
and mammals are all closely related to the viral gene v-src and to one another. It appears the 
vertebrate src gene has survived long periods of evolution without major change, implying 
that it is important to the well-being of the species in which it persists [6]. As a result, the 
genetic view of cancer-genes has for a long time its origins in virology. Retroviral oncogenes 
constitute the bridge between virus-induced tumors and tumors of all other etiologies: a 
cellular oncogene activated by viral transduction is a mere special example of the general 
phenomenon of genetic alterations that can convert important and useful growth regulators 
of the cell into driving forces of unbridled growth. Studies on tumor viruses had shown that 
viral genomes could carry individual genes that, when expressed in host cells, are both 
necessary and sufficient for the induction of oncogenic transformation. Such oncogenes 
became particularly interesting in retroviruses, because they turned out to be recent 
acquisitions from cellular genomes, pieces of host genetic information that were mutated, 
transduced and expressed as part of the viral life cycle.  
It was thus supposed that the biologically active cellular oncogenes are mutant forms of 
normal proto-oncogenes that differ in the regulation of their expression or in the structure 
and function of their gene products. Nevertheless, biologically active cellular oncogenes 
were also identified by the ability of tumor DNAs to induce transformation in gene 
transfer assays. Such experiments have led to the identification of more than a dozen 
distinct human oncogenes that are activated either by point mutations or by DNA 
rearrangements in human neoplasm, or by DNA rearrangements that occur in the process 
of gene transfer. Both somatic mutations and DNA rearrangements of such oncogenes 
activated in human tumors suggest implication of cellular oncogene activation in the 
pathogenesis of human cancers. Accordingly, in the last decade, many researchers focused 
their attention to studies extremely helpful in elucidating these questionable aspects by 
implying model organisms.  
1.2.1. Classification of cancer-genes 
The genetic injure present in a parental tumorigenic cell, if not correctable, is maintained 
such that it is a heritable trait of all subsequent generations cells. Most, if not all cancer cells 
contain genetic damage that appears to be the responsible event leading to tumorigenesis. 
Two types of genetic damage are generally found in cancer cells:  
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A. Dominant genetic damage- and the involved genes have termed  
proto-oncogenes 
A proto-oncogene is a gene whose altered protein product has the capacity to induce 
cellular transformation. The distinction between proto-oncogene and oncogene relates to the 
activity of the protein product of the gene. Therefore, an oncogene is believed to be a gene 
that has sustained some genetic damage and produces a protein capable of cellular 
transformation. The process of activation of proto-oncogenes to oncogenes can include 
retroviral transduction or retroviral or transposon integration, point mutations, insertion 
mutations, gene amplification, chromosomal translocation and/or protein-protein 
interactions. In general, proto-oncogenes have been classified based upon sequence 
homology to other known proteins or based on their normal function within cells [6]. As 
predicted, proto-oncogenes have been identified at all levels of the various signal 
transduction cascades that control cell growth, proliferation and differentiation. A common 
rule ascertains that proto-oncogenes which were originally identified as inhabitants in 
transforming retroviruses are designated as c- indicative of the cellular origin as opposed to 
v- to signify original identification in retroviruses. The list of proto-oncogenes identified to 
date is rather lengthy [3, 6].  
B. Recessive genetic damage- and the involved genes are variously termed tumor 
suppressors/ growth suppressors/ recessive oncogenes or anti-oncogenes  
There is an equally important category of cancer genes that contribute to tumorigenesis 
through a loss of function named tumor suppressor genes. In contrast to the growth 
stimulatory oncogenes, tumor suppressors normally function as attenuators and as 
inhibitors of growth. This category includes any gene that has the potential of becoming a 
constitutive growth stimulator and determinant of oncogenic cellular properties. The 
oncogenicity of these genes is therefore correlated with a gain of function.  
The normal versions of both oncogenes and tumor suppressor genes serve in diverse 
regulatory systems of the cell. Most proto-oncogenes encode for components of signal 
transduction pathways that convert an extracellular stimulus into a programmed pattern of 
gene expression. A functional relatedness of tumor suppressors is less apparent; some 
domains of tumor suppressor gene action include cell surface properties, signal 
transduction, gene transcription, DNA repair, and checkpoints for cell division [6]. 
1.3. Identification of new target cancer-related genes by insertional mutagenesis  
Insertional mutagenesis is a good mechanism for identifying new cellular proto-oncogenes, 
especially when correlating with neoplasms induction by different viruses or transposons. 
The activation of a candidate oncogene by such an insertion not only provides a means of 
identifying such potential oncogenes, but also permits their isolation as molecular clones for 
subsequent investigation. After integrating its viral/ transposon DNA, the virus/ transposon 
itself represents a marker that could help to isolate surrounding molecular clones. These 
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clones can furthermore provide the flanking genomic sequences, which can reveal the 
targeted proto-oncogene activated/ targeted by the insertion. A good example for this 
mechanism is provided by wnt-1 (previously called int-1) which is usually activated upon 
integration of MMTV proviral DNA in mouse mammary carcinomas, first isolated in the 
laboratory by Harold Varmus in 1982 [7]. The MMTV virus LTR end usually acts as an 
enhancer to elevate wnt-1 expression. The flanking DNA could have be cloned and then 
sequenced and it helped to elucidate the targeted wnt-1 gene sequence. So it was revealed 
that the wnt-1 genomic locus contains a transcriptional unit that was activated in tumors, 
either by upstream or downstream MMTV DNA insertion. The wnt-1 thus appeared to be a 
cellular oncogene because of its frequent activation by insertional viral spontaneous 
mutagenesis. But the designation of wnt-1 as a real oncogene was later decided when it was 
shown that introduction of this gene into cultured mammary epithelial cells induced 
abnormal growth characteristic of neoplastic transformation [8]. Although it was initially 
identified by indirect criteria of structural alteration in tumors, this demonstration of the 
biological activity of wnt-1 provided important subsequent justification for this approach for 
oncogenes isolation. Provirus insertional mutagenesis was also implicated in activation of 
other cellular proto-oncogenes, encoding for different growth factors. For example, the 
gibbon ape leukemia cell line MLA144 constitutively produces the interleukin-2 growth 
factor (T-cell growth factor), which appeared to be required for proliferation of these cells. 
Subsequent analysis of the interleukin-2 gene revealed that its constitutive expression is a 
consequence of the integration of gibbon ape leukemia virus DNA in the 3’ untranslated 
gene region [8].  
Most recently studies revealed that one of the best examples of how a transposon insertion 
could facilitate for oncogene/ candidate-cancer gene identification is given by numerous 
studies from Drosophila melanogaster. Using genetic methods in Drosophila null alleles of the 
P-transposon tagged genes can be generated by remobilizing the transposons and screening 
for transposon’s imprecise excisions. Different studies have also highlighted the power of D. 
melanogaster P-derivative transposons for examining cooperative interactions between tumor 
suppressors and oncogenes and for generating in vivo models of tumor development and 
metastasis [9]. Therefore, Drosophila is currently widely used as a model organism to explore 
the functions of different genes particularly those ones which are structural homologs of 
human oncogenes and tumor suppressor genes involved in a variety of tumors.  
1.4. How similar are the fruit flies and humans 
The fundamental aspects of the cellular biology, regulation the gene expression, neuronal 
connectivity, synaptogenesis, cellular signaling and cellular death are commonly accepted 
as being similar between humans and fruit flies. The structural homology between 
Drosophila and human genes has been revealed immediately after sequencing the 
D.melanogaster genome [10], and the human genome. Thereafter, the interest was focused on 
considerable studies using Drosophila as an experimental model for different human 
diseases. Numerous studies have been done to identify genes implicated in human 
pathologies that could be investigated in Drosophila. The most detailed study was done by 
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Reiter and collaborators [11] in 2001. Using the Online Mendelian Inheritance in Man 
(Homophila) database, Reiter and coworkers found that 714 of the 929 (77%) OMIM human 
disease gene entries have highly similar cognates in Drosophila, which were referring 
hereafter as “related genes”. These data can be accessed through 
http://superfly.ucsd.edu/homophila, and the query can be made by key word, disease name, 
fly gene, and OMIM number (Table 1).  
Table 1. How to query the Homophila database. The user enters the text query in the form of human 
disease name, OMIM number, fly gene name, or keyword search through the human disease entry box. 
A window with information on the disease name, and human and fly genes that match the key word 
query is opened. The user then can examine the details of an individual human-to-Drosophila BLAST 
comparison to get more information on the specific BLAST score, alignment, and other hits to this gene. 
In addition, transposons’ (P-element) information is found at this level [after 11].  
A list of disease phenotypes resulting from mutations in genes that are highly related to 
Drosophila genes has been categorized into various subclasses based on clinical phenotypes. A 
large number of human disease genes sharing Drosophila counterparts involved in different 
disorders such as: cancer, non-myelin associated neurological disorders, other developmental 
defects etc, has been therefore identified. Additional notable result of their study was that the 
great majority of Drosophila genes related to human disease genes (e.g. 395 genes out of 548) 
had not been analyzed by loss-of-function genetics by that time. Moreover, they found that 
many of these Drosophila related counterpart genes are marked by P-elements insertions in or 
near them (e.g., within 1 kb of the gene-coding region) and the P-element insertions were the 
only known alleles of those genes. Immediately after this study was published, using routine 
genetic methods in Drosophila, the possibility to create null alleles of these 56 P-element tagged 
genes was starting in different laboratories by remobilizing the P-elements and screening for 
imprecise excisions that delete all or parts of the coding regions. Thus, loss-of-function analysis 
has become possible for identifying the function of these “related genes”. Without the 
complete comparisons of the genomes in a database like Homophila, it would not be 
immediately obvious that genes e.g. responsible for human deafness could be functionally 
analyzed in an organism like Drosophila [11]. Surprisingly, the human genome is predicted to 
have only little over twice the number of genes found in flies and a comparison of both 
proteomes indicates 67% similarity at the amino acid level [10].  
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2. Why studying cancer in the fruit flies? 
The expansion of human cancer is a multistep route, involving the cooperation of mutations 
in signaling, cell-cycle and cell-death pathways, as well as interactions between the tumor 
and the microenvironment. In this context, to in vivo explore the steps of tumorigenesis, 
simple animal models are needed. The genetically amenable, multicellular organism, the 
vinegar fly, D.melanogaster, can be used to elucidate the functions of different human 
structural homologues whose mutations were identified in different types of cancers [12]. 
This choice is not surprisingly taking into account the research history in Drosophila and the 
contributions of the Drosophila genetics for understanding the signaling pathways 
implicated in oncogenesis, such as: Ras/MAPK, Notch, Wnt/wingless, hedgehog and BMP.  
D. melanogaster is an experimental model organism currently largely used for cancer 
research [13]. In 1916, decades before Drosophila would become one of the most popular 
models for studying many aspects of modern biology, the discovery of melanotic tumor-like 
granules in mutant larvae, by Bridges and Stark, first suggested that flies could develop 
tumors [14]. It took more than 50 years of genetic analysis to obtain convincing data which 
prove that insects can suffer from cancer [15]. Later, spontaneous mutations were identified 
causing the death of the animals at larval stages, because of overproliferation of certain 
internal tissues [16, 17]. Another study [18] showed that homozygous mutations in a series 
of genes from Drosophila can cause the appearance of tissue-specific tumors, which can affect 
either the embryonic or the larval development. Among these genes, the lethal (2) giant larvae 
(l(2)gl), has been the most studied. Homozygous mutations in l(2)gl produce malignant 
tumors in the brain and the imaginal discs. The l(2)gl gene was cloned, introduced back into 
the genome of l(2)gl-deficient animals and shown to restore the normal development [19], a 
process called “rescue-phenotype”. A mosaic screen for over-proliferation mutants has been 
used successfully to identify several novel tumor suppressors in flies, including the large 
tumor suppressor (lats; also known as wts) gene. Somatic cells mutant for lats undergo 
extensive proliferation and form large tumor outgrowths with morphological characteristics 
similar to those of human tumors, confirming that Drosophila can grow tumors that are 
comparable with those found in humans. The human homolog of the lats gene (LATS1) 
could be used to suppress tumor growth and rescue developmental defects in lats mutant 
flies, including embryonic lethality [20]. Studies in Drosophila of such genes provided 
information that was directly relevant to tumorigenesis in humans.  
In 2009, the second BioMed Conference from Barcelona entitled "Modelling Cancer in 
Drosophila" emphasizes again Drosophila as a model to elucidate human cancers. It was for 
the first time when a group of scientists came together to discuss the ways in which the fruit 
fly could provide novel contributions to the field of human cancers. For some of the 
presentations, discoveries in Drosophila were later validated in mammalian system or in 
humans [21]. So that, there is a large spectrum of candidate genes implicated in human 
pathologies that can be studied in Drosophila, and the lack of redundancy can simplify the 
analysis of biological process in the fly [22]. The functional orthology between Drosophila 
and human genes can be proved by rescue phenotype experiments (the equivalent of gene 
therapy) and it is working and gives surprising results.  
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2.1. Testing for preserved function between Drosophila genes and human 
counterparts  
There are a number of ways to test the function of a foreign gene/ protein in transgenic 
Drosophila. Homologs of a fly gene for which mutants exist can be tested for the ability to 
rescue the fly mutant phenotype. If the fly counterpart has dominant effects or if one might 
expect dominant effects as a result of the function of the protein in vertebrates (such as for a 
dominant oncogene or disease gene), then another test is to determine whether the 
vertebrate homolog can induce similar dominant phenotypes in flies. There are examples of 
dominant oncogenic mutations leading to a form of the protein that also functions 
dominantly in the fly [23]. In some cases, expression of vertebrate/human genes in fruit flies 
has demonstrated that a conserved function of the vertebrate and fly genes is 
autoregulation; thus, the vertebrate protein (frequently a transcription factor) turns on 
expression of the endogenous fly counterpart. If one has mutants in the fly gene involved. 
Then, it is possible to test for functional conservation in the genetic background of a protein 
null mutant of the fly gene and, hence, address broader aspects of functional conservation.  
Herein are presented some results of a study concerned on the clarification of the putative 
functional conservation between DmManf gene from Drosophila (previously called ARP-like 
for arginine-rich protein-like), and its counterpart- the human Manf gene (Mesencephalic 
astrocyte-derived neuroptrophic factor), which was found to be implicated in various human 
pathologies, including cancer.  
2.2. Exploration of the DmManf in comparison with Manf putative oncogene 
from human 
Mesencephalic astrocyte-derived neurotrophic factor, DmManf gene is referred in FlyBase by 
the symbol CG7013 (CG, computed gene). It has the cytological map location 89B19, in the 
right arm of the 3rd chromosome. The molecular function is unknown. Previously, it was 
shown that a P{EP} transposon insertion at the position –157 upstream of the 5’UTR region 
of the Manf gene does not affect the Manf gene function [24].  
The DmManf gene contains 1436 nucleotides and encodes for a protein of 173 amino acids. In 
the fruit-fly stock EP(3)3171 the DmManf gene is associated with a P derivative transposon. 
In general, transposable elements insertion’s are extremely powerful means of gene 
disruption. The transposon associated with DmManf gene was symbolized by P{EP}EP3171 
and was first inserted in the 5’UTR region of DmManf gene, and then, could be mobilized 
generating mutant alleles of the targeted gene.  
The human Manf counterpart gene, previously named ARP (from Arginine-Rich Protein) is 
located in the chromosomal band 3p21.2, a region that is frequently deleted in a variety of 
solid tumors. It encodes for a protein highly conserved in evolution. First oncological 
information was given by Shridhar and coworkers [25, 12] who reported an ATG-to-AGG 
transversion in codon 50 of the ARP gene or deletion of codon 50 in different tumor types 
including 10 of 21 sporadic renal cell carcinomas. Later (1997), they observed the same 
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mutations in 11 of 37 pancreatic tumors. Either of the changes abolishes a methionine 
residue and gives rise to an uninterrupted string of AGG trinucleotides in the ARP gene and 
arginines in its predicted protein product. The finding of 4 other nucleotide substitutions in 
codon 50 that replaced methionine with 4 different amino acids other than arginine 
suggested that loss of this methionine residue is critical to a carcinogenic role of this gene.  
Their finding of an AGG-to-AAG (arg-to-lys) mutation in the adjacent codon 51 in 2 tumors 
emphasized further the importance of this region. Other evidence [25] suggested that only a 
single copy of the ARP/Manf gene is mutated in the cancer cells, indicating its possible 
causal role as an oncogene.  
Mesencephalic astrocyte-derived neurotrophic factor sequences are referring to a family of 
small proteins of approximately 170 residues which contain four di-sulfide bridges that are 
highly conserved, from nematodes to humans (Table 2).  
 
 Genes Proteins  
1 MANF,  H.sapiens
mesencephalic astrocyte-derived neurotrophic factor
NP_006001.3 
182 aa
2 MANF,  P.troglodytes
mesencephalic astrocyte-derived neurotrophic factor
XP_001169644.1 
246 aa
3 MANF,  C.lupus
mesencephalic astrocyte-derived neurotrophic factor
XP_850540.1 
179 aa
4 MANF,  B.taurus
mesencephalic astrocyte-derived neurotrophic factor
NP_001094681.1 
179 aa
5 Manf,  M.musculus
mesencephalic astrocyte-derived neurotrophic factor 
NP_083379.2 
179 aa 
6 Manf,  R.norvegicus
mesencephalic astrocyte-derived neurotrophic factor
XP_236614.3 
179 aa
7 Manf,  D.rerio
mesencephalic astrocyte-derived neurotrophic factor
NP_001070097.1 
180 aa
9 Manf,  D.melanogaster
Mesencephalic astrocyte-derived neurotrophic factor
NP_477445.1 
173 aa
10 AgaP_AGAP003016,  A.gambiae
AGAP003016-PA
XP_311862.3 
180 aa
11 Y54G2A.23,  C.elegans
hypothetical protein
NP_500273.2 
168 aa
Table 2. HomoloGene report showing the putative homologs of mesencephalic astrocyte-derived 
neurotrophic factor. The identification number of the protein, the size and their conserved domain 
architectures are are assigned (www.ncbi.nlm.nih.gov/homologene).  
The amino acid sequences of this highly conserved protein in evolution shows 51% identity 
on average between Drosophila Manf gene and the human Manf (Fig. 1).  
The higher homology revealed by the comparison of the whole aminoacid sequences of the 
Drosophila and human proteins (51% identity, 71% positives) as compared to the amino acids 
of the Saposin_like domains (41% identity, 58% positives) suggests that, in addition to the 
Saposin_like domain, there are other motifs which highlight the similarity or even identity 
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between the compared aminoacid sequences. These motifs could be important for a 
particular function of the protein and suggest a similar function of the two proteins. This 
remark is in agreement with a similar situation that was encountered when Drosophila lats 
and human LATS1 were compared [20]. Although the overall sequence similarity in the 
amino-terminal regions of these two proteins was lower (22% identity and 42% similarity) 
than in the kinase carboxy-terminal (74% sequence identity), stretches of highly conserved 
sequences have been identified in both proteins, and finally, they proved that the genes are 
even functionally conserved. Another similar study presents the case of Mgstl which 
encodes a protein similar to human mGST. Because the identity between both genes was 
45% but their hydrophobic profiles were also very similar, the authors’ expectation was that 
these genes share a functional similarity [26].  
 
Figure 1. Comparison between D.melanogaster Manf and human Manf sequences. „Query”= protein 
from human and „Sbjct= protein from Drosophila. Amino acids from Saposin-like domain are 
surrounded by green; bordered in blue is EF-hand domain. For detailes, see text.  
To study whether DmManf holds not only a structural, but also a true in vivo functional 
similarity with its human counterpart, we mobilized the P{EP}EP3171-element from the 
EP(3)3171 line to obtain specific mutant alleles of the DmManf gene. Different mechanisms 
of repairing the double-strand break generated by the P{EP} excision induced a variety of 
new genetic variants, including loss-of-function DmManf alleles [27].  
In this study we took advantage of our first reported loss-of-function mutant DmManf allele, 
namelythe ManfΔ1151 (GenBank ID: DQ649527). The ManfΔ1151 allele was isolated in Ex.35 
mutant line (Fig. 2). By DNA sequencing of the specific mutant amplicon we discovered that 
the Ex.35 mutant line contains a deletion of 1278 bp that removes part of the intergenic 
region, the 5’UTR and almost the whole coding region of the DmManf gene, leaving behind 
the distal end of the last exon and the 3’UTR region (Fig.2 Ba) and is affecting only the 
DmManf gene.  
The ManfΔ1151 allele from Ex.35 line proved to be homozygous lethal. To define the lethal 
phase during development, we took advantage of the GFP (Green Fluorescent Protein) marker 
present in the Drosophila balancer chromosome TM3SerGFP, which could help distinguishing, 
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Figure 2. The structure and deletion breakpoints of P{EP}EP3171 homozygous lethal allele found in 
Ex.35 line. A: The genomic context including Drosophila Manf and CG14879 genes separated by 141bp 
intergenic region and transcribed in opposite direction. Δ stands for P{EP}EP3171 original insertion site. 
Exons are indicated by filled boxes, introns by empty boxes. Nucleotide numbers are assigned for the 
exons. B): The lethal ManfΔ1151 alele genomic deletion is indicated by the dashed line. The numbers of 
nucleotides are assigned for each exon [after 27].  
under an UV source, the GFP heterozygous individuals and non-GFP homozygous 
individuals. Therefore, after letting Drosophila females from Ex.35 line to lay eggs onto Petri 
dishes containing appropriate culture medium, we followed the development of the 
embryos and larvae comparing the numbers of the heterozygous and homozygous 
individuals. Starting with 594 embryos, we noticed that the number of the homozygotes was 
continuously decreasing during the subsequent developmental stages. As it revealed, the 
homozygous lethality was polyphasic, the homozygotes mostly died in the embryonic and 
1st instar larval (L1) phases, although L2 stage escapers were also found. Among the counted 
3rd stage larvae, two non-GFP excapers were found. One of them was transferred onto 
another culture plate and observed for several days. This mutant L3 larva contained some 
internal „holes”, i.e. empty, transparent spaces similar to that ‘‘empty’’ spaces found in 
another DmManf specific mutant, from a similar study [23]. First these homozygous larvae 
atypically wander away from the food, and then move more slowly, and finally freeze 
immobilized but still responding to touch. It was unable to enter the pupal stage and died 
keeping the phenotype described before. Homozygous mutant adults for ManfΔ1151 allele 
were never found. These empty „holes” remained unchanged during the observation 
period, suggesting that the pupae died inside, probably after several unsuccessful 
encapsulation immune reactions by which lammellocytes should encapsulate melanise and 
kill the parasites, fungi or even abnormal cells- such as tumor cells (Fig. 3).  
Most of the Drosophila overgrowing mutations are late larval or pupal lethal and affect the 
adult organ rudiments, imaginal discs, while leaving the other larval tissues necessary for 
larval survival mostly unaffected [28, 16]. The majority of such mutations display a 
prolonged larval period, also seen in the case of ManfΔ1151mutant, which can be explained by 
the presence of non-differentiating growing imaginal rudiments preventing ecdysone 
release [29].  
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While DmManf recently [23] was found to be required during the maturation of the 
embryonic nervous system for maintenance of neuronal connectivity, there were also 
indications (http://superfly.ucsd.edu/homophila/) of a possible role of Manf /ARP in human 
tumor formation [12, 25].  
  
Figure 3. Heterozygote and homozygote pupae from Ex.35 line. a) Ex.35 heterozygous control pupae 
(genotype: ManfΔ1151/TM3SerGFP); b) Ex.35 homozygous pupae (genotype: ManfΔ1151/ ManfΔ1151); arrows 
show the internal holes in the dead pupa.  
A wealth of data support the view that cancer is a multistage disease progressing via the 
accumulation of multiple genetic changes lesions that compromise the normal control of cell 
proliferation, survival, differentiation, migration and social interactions with neighboring cells 
[1]. It is also important to note that apparently phenotypically similar cancers may arise 
through different combinations of lesions: there are likely many different routes to cancer even 
in the same cell type. Many key cancer –relevant signaling pathways may be activated or 
inactivated by mutations at various points that could result in largely identical cell behavior.  
From this point of view, interesting cancer-like phenotypes were observed for different 
mutants previously obtained after P{EP}EP3171 transposon mobilization, from the DmManf 
gene vicinity [27]. The most aggressive cancer-like phenotypes which appeared in our 
mutants either killed the adult flies, e.g. in the case of Ex.29 mutant (Fig. 4) or let the adults 
survive, although they expressed in all the body melanotic tissue/nodules, in both females 
and male, e.g. in the case of A26.1 mutant (Fig. 6). Symbols and numbers in the mutant 
names designate different lines obtained from different P{EP}EP3171 mobilization 
experiments  [27]. 
   
Figure 4. Larval and pupal phenotypes found in the Ex.29 mutant. a. Larvae and pupae containing 
melanotic masses; b. dissected homozygous mutant larva in the IIIrd instar enclosing melanotic masses; 
c. The gut surrounded by melanotic masses. The arrows label melanotic masses. The Ex.29/Ex.29 
homozygote mutants never developed as adults.  
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The appearances of the melanotic masses in flies were extensively characterized. Although 
the Toll pathway seems to be responsible for the formation of melanotic masses in Drosophila 
[30], other genes could also be implicated upstream of downstream of this well 
characterized pathway. Spectacular results were obtained by investigating the ultra-
structure of the interesting melanotic masses found in case of Ex.29 mutant under the 
electron microscope. After dissecting normal and melanotic gut of the Ex29/Ex29 
homozygote mutant 3rd instar larvae, several sections were examined under the electron 
microscope (Fig. 5). We noticed that in the cells of control normal gut the nucleus revealed a 
typical structure with nuclear envelope, caryoplasm and nucleolus (Fig 5a). Caryoplasma, 
the fundamental substance of this nucleus appeared typical, as a protein gel with the 
embedded chromosomes and a nucleolus. Chromatin displayed a fibrillar structure, 
consisting mainly of DNA associated with histones and non-histone proteins. Chromatic 
substance of the nucleus become visible as a network, resulting from a strong 
despiralization, hydration, swelling, dragging and overlapping events of the chromosomes. 
In some parts, the chromatic substance disclosed more condensed probably corresponding 
to heterochromatic areas.   
   
Figure 5. Electron microscopic images after micro-dissection of Ex.29 homozygote 3rd instar larval gut; 
a. Nucleus and nucleolus of a normal gut cell. Magnification is 8640X; b. Dissection through melanotic 
“young tumor”- light black masses; the nucleus has a lobated edge, magnification 8640X; c. Dissection 
through melanotic “old tumor” -dark black masses, showing a nucleus without nucleolus. 
Magnifications 12400X. N- Nucleus; n- nucleolus; NE- nuclear envelope, V- vacuole; Cr- chromatin.  
Nucleolus, another important cellular structure displayed an oval shape with irregular 
contour (Figs. 5a, 5b), without specific membrane, being surrounded by a network of 
chromatic filaments of nuclear origin which twisted into perinucleolar chromatin. As 
typical, is prearranged in a fibrillar-granular structure consisting of fibrils and ribo-nucleo-
proteinic granules, like ribosomes.  
In contrast, in the „old tumor” dark black masses, resembling senescent cells (Fig. 5c) 
appeared having ceased its function, many structural changes occurring probably due to the 
intensification of autolitic processes. As a result, the cytoplasmic content decreased 
significantly, most of the cellular volume being replaced by the vacuolar system. In this cell 
the nucleus still persists, although the nucleolus have disappeared. Only a few blocks of 
chromatin and an increased number of autolytic vacuoles can be detected. These changes 
lead to the idea that such a cell is doomed to apoptosis. Other notable melanotic-like nodule 
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phenotype was observed in case of the A26.3 mutant stock, which contains DmManfA26.3 
allele, carrying a residual part from the original P element insertion (GenBank ID: 
HQ623183). The stereomicroscopic examination of these mutants showed mild melanotic 
masses in the larvae (Fig. 6).  
  
Figure 6. The A26.3 mutant phenotype is shown. a. Melanotic nodules in the adult flies, both in males 
and females. b dissected adult female carrying black melanotic nodules/ pseudo-tumors.  
Particular mutants expressing characteristic melanotic phenotype were also obtained in 
other insertional/ excisional P element mutagenesis experiments [31]. As it was shown 
previously, mutations in ~30 genes that regulate different pathways and developmental 
processes in Drosophila can cause a melanotic phenotype in larvae. The observed melanotic 
masses were generally linked to the hemocyte-mediated immune response. In general, the 
melanotic masses can be subdivided into melanotic nodules engaging the hemocyte-
mediated encapsulation and into melanizations that are not encapsulated by hemocytes [31]. 
With rare exception, the encapsulation is carried out by lamellocytes. Encapsulated nodules 
are found in the hemocoel or in association with the lymph gland, while melanizations are 
located in the gut, salivary gland, and tracheae. These results can show that the phenotype 
of each mutant not only reflects its connection to a particular genetic pathway but also point 
to the tissue-specific role of the individual gene.  
Half a century ago, melanotic tumors in Drosophila larvae and adults were viewed as the 
equivalent of cancer and as events of controlled histological differentiation that could be 
manipulated genetically. The participation of blood cells in the formation of some melanotic 
tumors was reported at about the same time [32, 33]. Black melanotic spots are found in a 
number of different mutants and have been called, interchangeably, melanotic tumors or 
pseudotumors. These ‘‘tumors’’ are usually not invasive and involve tumorous overgrowth 
only in some instances. Therefore it is generally accepted to use the term ‘‘melanotic 
masses’’ to describe the phenotype generally and ‘‘melanotic nodules’’ and ‘‘melanizations’’ 
to describe more specific phenotypes.  
Experiments in our laboratory indicated that an artificial transposon, P{EP}EP3171, when 
mobilized [27] could induce variable mutant genotypes and phenotypes resulting in a 
polyallelic series of the DmManf and/ or other interactor genes, including melanotic masses 
and nodules. This is not particularly suprising, taking into account other genes, e.g. the deep 
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orange (dor) gene, whose poly-alellic series affect different functions resulting in lethality, 
male sterility, sterility with maternal effect, or simple changes in the eye color [34]. We also 
found Drosophila mutants with paternal effect sterility, which could give away DmManf 
gene’s pleiotropic functions. By investigating all these isolated alleles we can reach 
comprehensive understanding of the role of the DmManf gene.  
2.3. Application of the rescue phenotype (gene therapy) technique in flies 
Gene therapy consists of the insertion of genes into an individual's cells and tissues to treat a 
disease, and hereditary diseases, in which a defective mutant allele is replaced by a 
functional one. Although the technology is still in its infancy, the researchers have already 
successfully tested it in Drosophila, for homozygous lethal mutations of the l(2)gl [19] or the 
lats gene [35], which could be saved by the orthologous genes from human: Hugl-1, scrib, dlg 
[36] etc. Therefore, when expressing a foreign gene in the fly in a tissue that normally does 
not express any such gene, screening of interacting proteins will be useful for understanding 
the function of the gene in its normal cellular context. It is important to assess whether any 
phenotypic effects observed in the fly accurately reflect conserved functions of the 
vertebrate protein under scrutiny. For example, will vertebrate anti-apoptotic genes block 
Drosophila programmed cell death? Will the vertebrate homolog, like its fly counterpart, 
direct ectopic tissue formation in the fly? If the vertebrate cDNA induces a dominant effect, 
is that effect the result of elevated levels of a normal activity of the protein (a hypermorphic 
effect) or of a new activity of the protein that may have little to do with its normal function 
(a neomorphic effect). Neomorphic effects, for example, might be the result of subcellular 
mislocalization of the vertebrate protein in the fly. To what degree does the pathology of a 
human disease gene reflect biological effects known to occur in humans or vertebrate 
models, and can these effects be faithfully replicated in the fly model? These are, of course, 
specific issues that vary for any one gene of interest, and they are critical to consider.  
2.3.1. DmManf is the true ortholog of the human Manf putative oncogene  
To investigate whether human Manf is able to compensate for the loss of function of 
DmManf mutants, we carried out rescue experiments with UAS-HsManf transgenic flies. We 
applied the gene therapy (rescue phenotype) procedure to the Ex.35 mutant which contains 
the loss-of-function allele ManfΔ1151, and shows lethal phenotype. First, we verified if the 
ManfΔ1151 mutant lethality was solely the result of the DmManf deletion, by inducing the 
ubiquitous ectopic expression of UAS-DmManf in the DmManfΔ1151 homozygote mutant 
background using the Actin-GAL4 driver (Fig. 7). Then, the ubiquitous Actin-GAL4 UAS-
HsManf expression was tested if it is also able to rescue the adult lethality of DmManfΔ1151 
homozygote mutants (Fig.7).   
We proved that the lethality was only caused by deletion of DmManf demonstrating that 
DmManf is important at least for the normal development and essential for viability. The 
rescue percentage of adult flies was similarly obtained when using separately the Drosophila 
and the Human Manf transgenes, driven by the ActinGal4 driver. These results demonstrate 
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that DmManf is the fruit fly functional ortholog of human Manf, and that fruit fly and human 
Manf share a yet unknown cognate receptor, essential for viability and normal 
development.  
 
 
Figure 7. The lethality of DmManfΔ115 adults is rescued by ectopic UAS-DmManf and UAS-HsManf 
expression with the ubiquitous Actin-GAL4 driver. The proportion of rescued adults relative to all 
adults is presented; 100% indicates the maximum expected value of complete rescue estimated by 
Mendelian inheritance.  
Herein is described a pilot experiment that supports the evolutionary conservation of the 
Manf gene functions’ in the fruit fly- Drosophila melanogaster and its important role in 
deciphering human pathologies. Our results complement previous results [23] when 
DmManf mutant (namely DmManfΔ96) lethality rescue- phenotype experiment resulted in 
complete larval rescue up to the pupal stage [23]. These authors were using 69B-GAL4 
driving the transgenic DmManf expression in epidermis and CNS, proving the importance 
of DmManf expression in both tissues in the fly. They also proved that DmManf is required 
for the maintenance of the DA neurites but not the neurites of serotonergic or the 
subpopulation of motoneurons. Surprisingly, despite the axonal degeneration in DmManf Δ96 
mutant larvae, the cell body of DA neurons persists. Moreover, some DA neurons but not 
their neurites persist even when their death was ectopically triggered by over expression of 
the proapoptotic proteins. Thus, programmed cell death in the Drosophila DA neurons seems 
to follow a ‘‘dying-back’’ pattern where the neurites degenerate first followed by the death 
of the cell body [23, 37]. Whether DmManf is a bona fide NTF promoting the survival of DA 
neurons remains, however, open as the mutant larvae died before it could be judged [23]. By 
TEM analysis, the elimination of DmManf causes cell death resembling caspase independent 
cell death, characterized by swelling of organelles, and the appearance of ‘‘empty’’ spaces [23, 
38]. Similar observations were also found in the case of our mutant Ex.35, which contains the 
DmManfΔ115 allele (see Fig. 3).  
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By the experiments involving DmManf gene from Drosophila presented here, some scientific 
data about the yet unknown role of this gene was obtained. We completed a first pilot 
phenotypic rescue of our DmManf deficient animals. It still remained unclear if the DmManf 
is a true oncogene or a tumor-suppressor gene. We assumed that a real cancerous 
phenotype could have not appeared in the Ex.35 mutant, either because DmManf gene might 
not be a canonical oncogene, or because while DmManf although preserved a particular 
function in the cancerous process, other additional mutations were simultaneously needed 
for the cancerous phenotype to appear. It is accepted that for the initial expansion of a cell 
clone more than one mutation is usually needed. Work in several laboratories sustain that in 
certain cases the mutational route to cancer may be either short (in genetic terms) with as 
few as two interlocking mutations required for initiation or progression of cancer, or long, 
and these instances can be easily clarified routinely in studies which involve animal models.  
3. Materials and methods 
Drosophila strains: For genetic nomenclature, cytology and description of mutations and 
chromosomes see [39] and Flybase [40]. Drosophila strains used are: w;EP(3)3171/TM3SbSer 
[24], w;TM3SerGFP/TM6TbSb, Ex.35/TM3, Ex.29/TM3, A26.3/TM3, Actin-GAL4/SM6Cy. For 
the phenotypic rescue experiments, the transgenic stocks UAS-DmManf and UAS- 
HumanManf were received as gifts from Dr. T.I.Heino. Fly crosses were done on standard 
cornmeal-yeast-agar medium, at 25°C.  
Phenotypic rescue experiments. The transgenic lines for UAS-DmManf and UAS-HsManf 
were recombined together with Actin-GAL4 driver, a GAL4 line of ubiquitous expression, 
on the DmManfΔ115 mutant background. For each experiment 3 independent crosses were 
made and transferred twice to fresh vials; progeny from all vials of each cross was counted, 
and the proportion of rescued adults relative to all adults was calculated.  
StereoMicroscopy and Image Analyses: Larval and pupal images were taken through an 
Olympus SZX7 stereo-microscope equipped with an Olympus DP70 camera.  
Electron Microscopy (EM) Analyses. The gut and melanotic tissues isolated from dissected 
Ex.29 homozygous larvae were fixed in 4% glutar-aldehyde in 0.1M sodium cacodylate 
buffer, pH7.3, 4h at 40oC and post-fixed in 1.5 % osmium tetroxide in the same buffer. They 
were then dehydratated in a graded ethanol series (30%, 50%, 70%, 90%, 95% and 100%) and 
embedded in Epon 812. The samples were sectioned on an ultra microtome, stained in 4% 
aqueous uranyl acetate, post-stained with lead citrate and examined with a Philips 201 
electron microscope.  
4. Conclusions 
Cancer can be measured as a complex multistep pathology that requires the accumulation of 
several mutations giving to cells an aberrant proliferative advantage, improved resistance to 
pro-apoptotic stimuli and loss of differentiation markers. Increasing evidences underline the 
importance of the tumor microenvironment in the growth of cancer cells. Since it has been 
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shown to exert both pro- and anti-tumoral effects, the role of the immune system in fighting 
cancer progression has been contradictory. Due to the simplicity of genetic manipulations, 
Drosophila research could bring meaningful insights to our understanding of the 
mechanisms of communication between cancerous and normal cells, as well as between the 
tumor tissue and the immune system. Although it still remained unclear if the Manf gene 
from Drosophila is a true oncogene or a tumor-suppressor gene, we assumed that DmManf 
gene could play a particular function in the process and probably other additional 
mutations are simultaneously needed for the cancerous phenotype to become visible. Efforts 
to use Drosophila to explore issues specific to cancer will keep on growing. Drosophila is 
being used for what it does best: identifying novel oncogenes and tumor suppressors, and 
linking cancer-related genes together into complex signaling pathways [9]. The use of whole 
organisms in vivo is generally considered as being essential for understanding the 
tumorigenesis.  
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